Acalabrutinib and PCE Dispertab
Determining the interaction of Acalabrutinib and PCE Dispertab and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Erythromycin can significantly increase the blood levels of acalabrutinib. This may increase side effects such as nausea, vomiting, diarrhea, abdominal pain, hemorrhage, development of other cancers, abnormal heart rhythm, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. Physiologically based pharmacokinetic (PBPK) simulations showed that moderate CYP450 3A4 inhibitors (erythromycin, fluconazole, diltiazem) increased acalabrutinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 2- to nearly 3-fold. Increased acalabrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.
MANAGEMENT: The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Generic Name: acalabrutinib
Brand name: Calquence
Synonyms: n.a.
Generic Name: erythromycin
Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV
Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Acalabrutinib-PCM-LA
- Acalabrutinib-Pedia Care Multi-Symptom Cold
- Acalabrutinib-Pedia Poly-Vite Drops with Iron
- Acalabrutinib-Pedia Relief Cough-Cold
- Acalabrutinib-Pedia Tri-Vite Drops
- Acalabrutinib-Pedia-Lax
- PCE Dispertab-ACAM2000
- PCE Dispertab-Acanya
- PCE Dispertab-Acarbose
- PCE Dispertab-AccessPak for HIV PEP Basic
- PCE Dispertab-AccessPak for HIV PEP Expanded with Kaletra
- PCE Dispertab-AccessPak for HIV PEP Expanded with Viracept